Boehringer Ingelheim Limited

Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone: +44 (0)1344 424 600
Fax: +44 (0)1344 741 298
WWW: http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line: +44 (0)1344 741 286
Medical Information e-mail: medinfo@bra.boehringer-ingelheim.com

Summary of Product Characteristics last updated on the eMC: 17/03/2009
SPC Combivent Metered Aerosol

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/03/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.8 has been updated as follows:

- addition of frequencies based on clinical trials and ordering of information under SOC

- rewording to reflect MedDRA terminology

- 2 new side effects based on last PSUR (Atrial fibrillation and Myocardial ischaemia)

- inclusion of side effects previously only addressed in special precautions and warnings section

 

Section 10 – date has been revised

Updated on 14/01/2009 and displayed until 17/03/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Nov-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.4 Special warnings and precautions for use has been updated in line with the current CCDS documents for this product as detailed below:

 
removal of the heading Occular complications from the 2nd paragraph

addition of bladder-neck obstruction to paragraph 5 and minor changes to the ordering of the information to facilitate the inclusion of this

addition of a information on rare occurrences of myocardial ischaemia associated with salbutamol (paragraph 6)

 

Updated on 04/04/2008 and displayed until 14/01/2009
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   03/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 6.5 of this SPC has been revised to delete the non-marketed 5ml and 15 ml canisters.  Section 10 has also been updated.

Updated on 01/09/2006 and displayed until 04/04/2008
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 10 (date of (partial) revision of the text
Date of revision of text on the SPC:   06/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 3.   Addition of:  Pressurised aluminium container closed with a metering valve containing a creamy-white suspension inserted into a grey plastic actuator (mouthpiece).
 
Section 4.2.  Addition of:  As the container is not transparent it is not possible to see when the contents are used up, but shaking the container will show if there is any remaining fluid.

The mouthpiece should always be kept clean and can be washed with warm water. If soap or detergent is used, the mouthpiece should be thoroughly rinsed in clear water.
 
Section 4.8.  Pruritis added to allergic-type reactions.
 
Section 6.4.  Addition of:   The canister contains a pressurised liquid.  Do not expose to temperatures higher than 50°C. Do not try to            open,  puncture or burn the canister even when apparently empty. 
Updated on 17/02/2005 and displayed until 01/09/2006
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 10 (date of (partial) revision of the text
Updated on 24/07/2001 and displayed until 17/02/2005
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 14/06/2000 and displayed until 24/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 14/06/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ipratropium bromide
   salbutamol sulphate